STAT

Opinion: CRISPR-Cas9 commercialization may be slowed by delivery and manufacturing challenges

As the gene-editing community focuses on the ethics of using this technology, it also needs to solve the more prosaic problems of CRISPR-Cas9 delivery to cells and manufacturing.
To move gene editing toward commercialization, companies will have to solve delivery and manufacturing issues. Source: Mark Schiefelbein/AP

The news in November that a Chinese scientist may have edited the genes of embryos, resulting in the birth of two baby girls, reminds us that gene editing is still an exciting — and often controversial — field.

At the recently concluded J.P. Morgan Healthcare Conference in San Francisco, the sense of foreboding about the future of this industry had dissipated. As I spoke with my colleagues in the field and executives from other companies, I got a sense that we were confident that gene editing is poised on the edge of great success, with therapies already approved by the U.S. Food and Drug Administration and the European Medicines

You're reading a preview, sign up to read more.

More from STAT

STAT9 min read
While Addiction Crisis Raged, Many Surgeons Overprescribed Opioids, Analysis Shows
Amid the addiction crisis, thousands of surgeons continued to hand out far more pills than needed for postoperative pain relief.
STAT2 min read
A New ‘DNA Microscope’ Peers Deep Inside Living Cells
A “DNA microscope” shows locations of DNA (and its cousin, RNA) in a cell and their precise nucleotide sequences.
STAT9 min read
Employers Are Steering Workers Toward A Controversial Stem Cell Therapy
A stem cell clinic has persuaded over 100 employers to include its controversial therapy in their health insurance plans.